In addition, increasing pediatric data is emerging for BRAF and MEK inhibitors in the treatment of surgically inaccessible gliomas that express BRAF V600E mutations, with an acceptable side effect profile in this age group [1, 3, 4, 16, 18, 29]. The gene discussed is MAP2K7; the disease is central nervous system cancer.